Mp26-09 Effect of Perioperative Tamsulosin on Successful Ureteral Access Sheath Placement and Stent-Related Symptom Relief: A Double-Blind, Randomized, Placebo-Controlled Clinical Trial

You have accessJournal of UrologyStone Disease: Medical & Dietary Therapy (MP26)1 May 2024MP26-09 EFFECT OF PERIOPERATIVE TAMSULOSIN ON SUCCESSFUL URETERAL ACCESS SHEATH PLACEMENT AND STENT-RELATED SYMPTOM RELIEF: A DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED CLINICAL TRIAL Homin Kang, Jungyo Suh, Jung Hyun Shin, Han Kyu Chae, and Hyung Keun Park Homin KangHomin Kang , Jungyo SuhJungyo Suh , Jung Hyun ShinJung Hyun Shin , Han Kyu ChaeHan Kyu Chae , and Hyung Keun ParkHyung Keun Park View All Author Informationhttps://doi.org/10.1097/01.JU.0001009408.66023.77.09AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail Abstract INTRODUCTION AND OBJECTIVE: This study aimed to investigate the effect of taking tamsulosin prior to surgery on the successful insertion of a 14 French (F) ureteral access sheath (UAS) during the procedure, as well as the impact of pre-and post-operative tamsulosin use on symptoms related to the ureteral stent. METHODS: This was a randomized, single-center, double-blind, placebo-controlled trial of 200 patients undergoing retrograde intrarenal surgery. Patients received either tamsulosin (0.4 mg) or placebo from 1 week before the surgery until stent removal. The patients were randomly assigned to one of four groups: Group 1 received tamsulosin throughout the entire study period, while Group 2 received tamsulosin before surgery and placebo after surgery, Group 3 received placebo before surgery and tamsulosin after surgery, and group 4 took placebo before and after surgery. The ureteral stent symptom questionnaire was completed between postoperative days 7 and 14. RESULTS: In total, 160 patients were included in the analysis (G1: 40, G2: 43, G3: 36, G4: 41). Mean age was 55.0±11.0 years, and 48 were female (30.0%). In the group receiving pre-tamsulosin (G1+G2), the success rate of 14F UAS deployment was significantly higher compared to the pre-placebo (G3+G4) group (88.0 vs. 75.3%, p=0.038). Regarding the USSQ, no significant intergroup differences were found between four subgroups in domains of urinary (p=0.110), pain (p=0.185), sexual matters (p=0.523), and additional problems (p=0.511). The analysis of variance for the general health (p=0.047) and work (p=0.035) were statistically significant results, however, post-hoc analysis did not reveal statistical significance. CONCLUSIONS: Our results revealed that preoperative administration of tamsulosin improved the success of larger-sized UAS, while pre- and postoperative tamsulosin use did not significantly alleviate symptoms related to ureteral stent. Source of Funding: None © 2024 by American Urological Association Education and Research, Inc.FiguresReferencesRelatedDetails Volume 211Issue 5SMay 2024Page: e417 Advertisement Copyright & Permissions© 2024 by American Urological Association Education and Research, Inc.Metrics Author Information Homin Kang More articles by this author Jungyo Suh More articles by this author Jung Hyun Shin More articles by this author Han Kyu Chae More articles by this author Hyung Keun Park More articles by this author Expand All Advertisement PDF downloadLoading ...